CRM/Vault Specialist

CRM/Vault Specialist

Reports to CRM Manager

Opportunity

The CRM/Vault Specialist will be a member of the Global Marketing team for Menarini-Stemline, operationally responsible for Global (ex-US) CRM activities, with a focus on EU and MEA countries.

The main mission is to drive projects to support CRM/Vault related development and evolution, that resonate with the end user community whilst driving the leadership team's strategic initiatives.

The incumbent will manage CRM/Vault related tasks acting as point of contact with the regional/ markets and Commercial and Medical excellence leads.

Responsibilities

Operations and support

• Act as SME for Veeva CRM and Vault related technical and business topics.
• Support customer facing teams in EU-5 and key MEA countries in day-to-day CRM activities.
• Perform admin and configuration tasks, address and resolve issues, problems and change requests.
• Drive segmentation & targeting exercises with country commercial leadership, and if necessary, external consultants to ensure high quality impact of commercial team deployment.
• Assess, monitor and continuously enhance user adoption towards CRM and promote digital engagement.
• Enable tracking of key metrics for Commercial and Medical Excellence, provide leadership with periodic analytical progress reports and outcomes.

Project Management and Business Analysis

• Strategic design and rollout of CRM and Vault systems across EU & MEA countries, support geographic and product portfolio expansion targets through re-usable processes and ready-to-deploy systems.
• Interface between Menarini-Stemline and CRM/ Vault systems’ vendors and consultants.
• Accountable for Commercial and Medical CRM/Vault activities including the set up of business rules, with strong cross-functional collaboration with Medical and Market Access teams.
• Collaborate with country teams, including leadership, towards optimization of CRM/Vault systems.
• Propose and discuss with the leadership developments and upgrades of CRM/Vault system to ensure state of the art CRM/Vault systems in Menarini-Stemline.

Additional responsibilities

• Train and support users: Provide comprehensive training and ongoing support on CRM/Vault systems.
• Maintain knowledge base: Lead training sessions and update documentation for effective system usage.
• Optimise processes: Identify and implement improvements to streamline operations and enhance efficiency.
• Ensure compliance: Maintain adherence to policies, regulations, and security standards.

Skills/Knowledge

• Degree, preferably in Marketing and Sales, Information Systems, Business Administration and related disciplines.
• Minimum 3 years operational / technical expertise in CRM and Vault systems, in particular Veeva, and their application to the pharmaceutical industry.
• Experience with Vault systems, in a regional or global role would be a plus.
• Veeva CRM/Vault certification would be an asset.
• Project management, business analysis and analytical capabilities. Ability to understand business requirements and translate them into technical solutions.
• Data Analysis: Strong skills in analysing data to drive decisions and improve CRM processes.
• Effective verbal and written communication skills in English for training, support, and collaboration. Other European languages would be an asset.
• Ability to troubleshoot and resolve technical issues related to the CRM/Vault system. Experience in L2-L3 support is a valuable plus.
• Ability to manage multiple tasks and prioritise effectively. Self-starter with the ability to work with cross-functional teams to achieve common goals.
• Customer orientation, teamworking, collaborative and proactive aptitude.

Menarini Stemline is an equal-opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.